Evaluating the Role of Postmastectomy Radiation Therapy Based on Pathological Nodal Response in Clinical Nodal Positive Stage II-III Breast Cancer after Neoadjuvant Chemotherapy: A Multicenter Study of 1963 Cases from China

被引：0
作者：
Huang, Z. [1 ,2 ]
Wang, S. L. [2 ,3 ]
Tang, Y. [2 ,4 ]
Rong, Q. L. [1 ,2 ]
Zhu, L. [5 ]
Huang, X. B. [6 ]
Shi, M. [7 ]
Wang, W. H. [8 ]
Shen, L. [9 ]
Chen, J. Y. [10 ]
Zhang, J. [11 ]
Wu, H. F. [12 ]
Cheng, J. [13 ]
Liu, M. [14 ]
Ma, C. Y. [15 ]
Li, Y. X. [1 ,2 ]
机构：
[1] Chinese Acad Med Sci, Dept Radiat Oncol, Natl Canc Ctr, Canc Hosp, Beijing, Peoples R China
[2] Peking Union Med Coll, Beijing, Peoples R China
[3] Chinese Acad Med Sci, Natl Clin Res Ctr Canc, Canc Hosp, Dept Radiat Oncol,Natl Canc Ctr, Beijing, Peoples R China
[4] Chinese Acad Med Sci, Natl Clin Res Ctr Canc, Canc Hosp, Natl Canc Ctr, Beijing, Peoples R China
[5] Tianjin Med Univ Canc Inst & Hosp, Dept Radiat Oncol, Tianjin, Peoples R China
[6] Sun Yat Sen Univ, Ctr Canc, Dept Radiat Oncol, Guangzhou, Guangdong, Peoples R China
[7] Fourth Mil Med Univ, Xijing Hosp, Dept Radiat Oncol, Xian, Shaanxi, Peoples R China
[8] Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing,Dept Radiat Oncol, Beijing, Peoples R China
[9] Cent S Univ, Xiangya Hosp, Dept Oncol, Changsha, Hunan, Peoples R China
[10] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Radiat Oncol, Shanghai, Peoples R China
[11] Hebei Med Univ, Hosp 4, Dept Radiat Oncol, Shijiazhuang, Hebei, Peoples R China
[12] Canc Hosp Jilin Prov, Dept Radiat Oncol, Changchun, Jilin, Peoples R China
[13] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Ctr Canc, Wuhan, Hubei, Peoples R China
[14] Jilin Univ, Hosp 1, Dept Radiat Oncol, Changchun, Jilin, Peoples R China
[15] First Hosp Qiqihaer, Dept Radiat Oncol, Qiqihar, Peoples R China
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2019年 / 105卷 / 01期
关键词：
D O I：
10.1016/j.ijrobp.2019.06.395
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
16
引用
收藏
页码：S8 / S9
页数：2
相关论文
共 50 条
[41]   Nodal Response and Survival After Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive Breast Cancer: 20-Year Experience from a Single Institution [J].
An, Selena J. ;
Thai, Christine Hong Ngoc Che ;
Ismail, Sherin ;
Agala, Chris B. ;
Hoang, Van ;
Feeney, Timothy ;
Lillie, Margaret ;
Wheless, Amy ;
Selfridge, Julia M. ;
Ollila, David W. ;
Gallagher, Kristalyn K. ;
Carey, Lisa A. ;
Spanheimer, Philip M. .
ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (13) :8786-8794
[42]   Long-term outcome for neoadjuvant versus adjuvant chemotherapy in early breast cancer and the prognostic impact of nodal therapy response: A population-based study [J].
Liu, Xingrong ;
Bergman, Louise Eriksson ;
Boman, Caroline ;
Foukakis, Theodoros ;
Matikas, Alexios .
EJSO, 2025, 51 (03)
[43]   Comment on "Long-term outcome for neoadjuvant versus adjuvant chemotherapy in early breast cancer and the prognostic impact of nodal therapy response: A population-based study" [J].
Zhang, Wei .
EJSO, 2025, 51 (08)
[44]   The role of radiation therapy in clinically node-positive, pathological negative nodes after neoadjuvant chemotherapy in breast cancer patients: In sentinel node biopsy and trastuzumab era [J].
Joo, J. H. ;
Ki, Y. ;
Kim, S. S. .
ANNALS OF ONCOLOGY, 2019, 30
[45]   Accuracy of ultrasound-guided targeted fine-needle aspiration in assessing nodal response in node-positive breast cancer after neoadjuvant chemotherapy: a prospective feasibility study [J].
Wu, Si-Yu ;
Li, Jian-Wei ;
Wu, Huai-Liang ;
Shao, Zhi-Ming ;
Liu, Guang-Yu ;
Hu, Na .
BRITISH JOURNAL OF SURGERY, 2022, 109 (12) :1194-1197
[46]   Remarkable complete pathologic response rate after preoperative paclitaxel, gemcitabine, and trastuzumab chemotherapy in HER2 positive stage III/III breast cancer: a phase II multicenter study. [J].
Im, S-A ;
Lee, K. S. ;
Lee, E. S. ;
Kwon, Y. ;
Noh, D-Y ;
Park, I-A ;
Ahn, J-H ;
Ahn, J. S. ;
Kim, J. H. ;
Nam, B-H ;
Ro, J. .
CANCER RESEARCH, 2009, 69 (02) :331S-332S
[47]   Epirubicin, cyclophosphamide and pyrotinib followed by docetaxel, trastuzumab and pyrotinib as neoadjuvant therapy for stage II-III HER2-positive breast cancer: a single-arm, multicenter phase 2 trial [J].
Shi, Qiyun ;
Qi, Xiaowei ;
Tang, Peng ;
Fan, Linjun ;
Chen, Li ;
Wang, Shushu ;
Zhang, Guozhi ;
Wang, Mengyuan ;
Che, Hongying ;
Lv, Pengwei ;
Chen, Dejie ;
Hu, Jinhui ;
Li, Qiuyun ;
Zhang, Yanwu ;
Yu, Qiao ;
Yang, Kunxian ;
Zhong, Yuan ;
Chen, Chuang ;
Zhou, Zemin ;
Qian, Liyuan ;
Zhang, Jingwei ;
Ma, Mingde ;
Sun, Yi ;
Liu, Jiangbo ;
Zhang, Yi ;
Jiang, Jun .
CANCER RESEARCH, 2023, 83 (05)
[48]   Outcome prediction for clinical stage II and III ER+ Breast cancer based on treatment response, pathological stage, tumor grade, Ki67 proliferation index, and estrogen receptor status after neoadjuvant endocrine therapy [J].
Ellis, M. J. ;
Tao, Y. ;
Luo, J. ;
Evans, D. B. ;
Bhatnagar, A. S. ;
Chaudri, Ross H. ;
Von Kameke, A. ;
Miller, W. R. ;
Eiermann, W. .
BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 :S16-S17
[49]   Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial [J].
Huang, Liang ;
Chen, Sheng ;
Yang, Wentao ;
Xu, Binghe ;
Huang, Tao ;
Yang, Hongjian ;
Zheng, Hong ;
Wang, Yongsheng ;
Song, Erwei ;
Zhang, Jin ;
Cui, Shude ;
Pang, Da ;
Tang, Lili ;
Lei, Yutao ;
Geng, Cuizhi ;
Shao, Zhiming .
ONCOTARGET, 2015, 6 (21) :18683-18692
[50]   Prognostic factors of survival in node positive breast cancer patients after neoadjuvant chemotherapy in a large series after 5y follow-up: Can response overcome the poor prognosis of nodal stage? [J].
Fernandez, S. ;
Garcia, A. ;
Vethencourt, A. ;
Vazquez, S. ;
Petit, A. ;
Pla, M. J. ;
Ortega, R. ;
Perez, J. ;
Gil, M. ;
Ponce, J. ;
Pernas, S. ;
Lopez, A. ;
Falo, C. .
CANCER RESEARCH, 2019, 79 (04)
12345